First in Human Study for the Assessment of Safety and Initial Performance of the EAS1 System

Launched by SNIPE MEDICAL · May 16, 2024

Keywords

ClinConnect Summary

This clinical trial is testing a new treatment called the EAS1 system, which uses a method known as Irreversible Electroporation (IRE) to target lung cancer. The goal of the study is to evaluate how safe this treatment is and how well it works in patients who are eligible for surgery to remove their lung tumors. The trial is open to adults aged 18 and older who have a specific type of lung cancer and at least one tumor that is not larger than 30 millimeters.

To participate, patients must be able to provide informed consent and have a confirmed diagnosis of lung cancer that meets certain criteria. They should also be scheduled for surgery to remove their tumor and have enough healthy lung tissue around the tumor. Participants will undergo the treatment and will be monitored closely to assess their safety and the effectiveness of the EAS1 system. It's important to note that individuals with certain health conditions or recent infections may not be eligible for this trial. If you or a loved one are considering participation, the study team will provide more information about what to expect throughout the process.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Adult male and female subjects (age ≥18 years at the date of informed consent signature)
• • Subject is capable and willing to provide an informed consent
• • Subjects with a known diagnosis of lung cancer at cT1a-T1c, cN0 stages
• • At least one pulmonary tumor (primary or metastasis) ≤ 30 mm in maximal diameter, as confirmed by the latest standard of care imaging (CT/MRI), performed preferably up to 30 days prior to screening
• • Subjects who are scheduled or deemed eligible by a thoracic surgeon for lung tumor resection
• • Subject is able and willing to comply with the study procedures and visits
• • There is ≥ 5mm of nodule-free lung parenchyma between target nodule and pleura or fissure, as confirmed by the latest standard of care imaging (CT/MRI), performed preferably up to 30 days prior to screening
• • ECOG 0-1
• • Stable doses of concomitant medications for at least four (4) weeks prior to enrollment
• Exclusion Criteria:
• • An inability to provide informed consent
• • Subjects with contraindication for tumor resection
• • Subjects with life expectancy \<12 months
• • Target nodule is abutting main stem bronchus, main pulmonary vasculature, esophagus and/or trachea
• • Subjects with Forced Expiratory Volume (FEV1) \<50%
• • Total Lung Capacity (TLC)\< 80% of expected for age
• • Diffusing Capacity (DCO) \< 60% of expected
• • Oxygen saturation in free air of \<88%, or requiring more than 2 l/min oxygen to achieve saturation of 92%
• • PCO2 of ≥ 45mm/Hg
• • Subjects in exacerbations group E (high risk; ≥2 exacerbations per year or ≥1 requiring hospitalization and any level of symptoms)
• • Severe emphysema, Bullous Emphysema or chronic obstructive pulmonary disease (COPD) (GOLD III/IV)
• • Active and/or prolonged lung or bronchi infection, required an antibiotic treatment up to 21 days prior to screening and for more than 10 days of treatment
• • Known history or current evidence of a significant bronchiectasis
• • Evidence of lung Bullae the occupies more than one third of the lung intended for ablation
• • Previous surgery in the lung intended for ablation; thoracic major surgery at the side intended for ablation
• • Anticoagulation treatment that cannot be discontinued prior to the ablation, or a bleeding diathesis or platelets \<100 )K/µl)
• • Pregnant or breastfeeding female subjects or female subjects who plan pregnancy during participation in the study
• • Highly hypoxemic patients, according to investigator's discretion
• • Subjects with implanted metal or electronic thoracic devices objects (such as pacemaker) that cannot be removed prior to procedure
• • Subjects with contraindication for bronchoscopy
• • Participation in any other interventional clinical trial with medication, medical device and/or supplements within 30 days prior to informed consent signature
• • Any subject who, at the discretion of the investigator, may be jeopardized by study participation

Trial Officials